Aim This study developed two nomograms to predict the incidence of acute heart failure (AHF) in patients of atrial fibrillation (AF) and evaluated the predictive value of the nomograms. Method 18179 patients of AF from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database were analysed. The patients were randomly divided into two groups in a seven-to-three ratio to form a training cohort (n=12725) and a validation cohort (n=5454). Least absolute shrinkage and selection operator (LASSO) regression analyses were used to identify associated risk variables. Two nomograms were established to predict the rate of AHF in patients of AF for use by patients and clinicians, respectively. The new models were assessed in terms of the concordance index (C-index), the area under the curve (AUC) of receiver operating characteristic (ROC) analysis, calibration curve, and decision curve analysis (DCA). Results Least absolute shrinkage and selection operator (LASSO) regression analysis identified seven potential predictors of acute heart failure in nomogram 1 and three potential predictors in nomogram 2. Multivariate logistic regression analysis was used to evaluate the effects of these predictors and create final models. The concordance index values were 0.768 and 0.696, respectively. The areas under the curves for the training and validation sets in nomogram 1 were 0.768 and 0.763, respectively. The areas under the curves for the training and validation sets in nomogram 2 were 0.696 and 0.692, respectively. Conclusion The age, respiratory rate, fluid management, mean corpuscular hemoglobin concentration (MCHC), bicarbonate, blood urea nitrogen (BUN) and chloride were identified as predictors of the development of acute heart failure in patients with atrial fibrillation in nomogram 1. The charlson score, lods score and sapsII score were identified as predictors of the development of acute heart failure in nomogram 2. Our nomograms are reliable convenient approaches for predicting acute heart failure in patients with atrial fibrillation.

The authors have declared no competing interest.

N/A

No funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data generated or analysed during this study are included in this published article and its supplementary information files.